reports
Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Pl...
Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement BERKELEY HEIGHTS, N.J., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (NASDAQ: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced that it has entered into a securities purchase agreement with a select group of institutional accredited investors to sell securities in a private placement for aggregate gross proceeds of approximately $50.0 million, before deducting placement age...
Kalaris Therapeutics Reports Positive Initial Phase 1a Data for TH103 ...
Kalaris Therapeutics Reports Positive Initial Phase 1a Data for TH103 in Treatment-Naïve Neovascular AMD TH103 showed mean 10-letter gain in visual acuity and rapid, robust anatomic improvement at Month 1, following a single injection TH103 was generally well tolerated, supporting further dose escalation beyond 2.5 mg TH103 showed a 27 to 51-fold lower plasma Cmax by pharmacokinetic analysis compared with current leading agents, indicative of increased intraocular retention Accelerating enrollment in ongoing Phase 1b/2 multi ascending dose-finding study; preliminary efficacy and safety ...
Tenaya Therapeutics Announces Pricing of Public Offering
Tenaya Therapeutics Announces Pricing of Public Offering SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced the pricing of its underwritten public offering of 50,000,000 total units for gross proceeds of $60 million prior to deducting underwriting discounts and commissions and offering expenses. Tenaya intends to use the net proceeds from the offerin...
Tenaya Therapeutics Announces Proposed Public Offering
Tenaya Therapeutics Announces Proposed Public Offering SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that it intends to offer and sell units consisting of common stock and warrants to purchase shares of common stock. Tenaya may also sell to certain investors, in lieu of units, pre-funded units consisting of pre-funded warrants to purchase shares o...
Tenaya Therapeutics Announces Rapid Resolution and Lifting of Clinical...
Tenaya Therapeutics Announces Rapid Resolution and Lifting of Clinical Hold for MyPEAK-1™ Phase 1b/2a Clinical Trial of TN-201 Gene Therapy MyPEAK-1 Protocol Amendments Agreed Upon with FDA; Tenaya Implementing Changes with Sites SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced it has received official notification from the U.S. Food and Drug Admin...
Tenaya Therapeutics Reports Positive Interim Data from Cohort 1 of RID...
Tenaya Therapeutics Reports Positive Interim Data from Cohort 1 of RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy for Adults with PKP2-associated ARVC TN-401 was Well Tolerated at 3E13 vg/kg dose Robust Transduction and Demonstrated Increases in PKP2 Protein Levels in First Two Patients at Week 8 Clinically Meaningful Reductions in Arrhythmia Burden Observed in First Two Patients with More Than Six Months of Follow-Up Tenaya Management to Host a Webcast Conference Call Thursday, December 11 at 5:00 pm ET to Review Preliminary Results SOUTH SAN FRANCISCO, Calif., Dec. 11, 20...
Consumer Portfolio Services Inc: 1 director
A director at Consumer Portfolio Services Inc sold 100,000 shares at 8.690USD and the significance rating of the trade was 72/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last t...
MacroGenics to Participate in the 8th Annual Evercore Healthcare Confe...
MacroGenics to Participate in the 8th Annual Evercore Healthcare Conference ROCKVILLE, MD, Nov. 25, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that Eric Risser, President and CEO of MacroGenics, will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Thursday, December 4, at 7:55 am ET in Miami, FL. A webcast of the presentation may be accessed under "Events & Presentations" in the Investor Relations section ...
Xos Extends Profitability Streak with Strong Q3 2025 Performance and P...
Xos Extends Profitability Streak with Strong Q3 2025 Performance and Positive Operating Cash Flow Delivered 130 units and generated $16.5 million in revenue Achieved 15.3% Gross Margin and a second consecutive quarter of positive free cash flow Continued cost discipline with 24% year-over-year reduction in third quarter operating expenses LOS ANGELES, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Xos, Inc. (NASDAQ: XOS) (“Xos” or the “Company”), a leader in electric commercial vehicles and mobile charging solutions, today reported financial results for the third quarter ended September 30, 2025. ...
MacroGenics Reports Third Quarter 2025 Financial Results and Provides ...
MacroGenics Reports Third Quarter 2025 Financial Results and Provides Update on Corporate Progress Achieved additional $75 million in partnering proceeds from Sanofi and GileadGranted license to additional preclinical program to Gilead that leverages MacroGenics’ novel T-cell engager platformRealigned pipeline priorities by ending development of lorigerlimab in prostate cancer while continuing development in ovarian cancerCash runway guidance extended into late 2027 ROCKVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on ...
Kalaris Reports Third Quarter 2025 Financial Results and Provides Busi...
Kalaris Reports Third Quarter 2025 Financial Results and Provides Business Updates Phase 1a Single Ascending Dose trial remains on track for initial clinical data to be reportedby year end 2025 Phase 1b/2 Multiple Ascending Dose trial currently enrolling, intended to inform dose selection for potential Phase 3 development program; initial clinical data expected in 2H 2026 Recent significant corporate milestones include the selection of a CDMO, CFO hire, and opening of corporate headquarters Cash, cash equivalents and short-term investments of $77.0M as of September 30, 2025, expected to...
CPS Announces Third Quarter 2025 Earnings
CPS Announces Third Quarter 2025 Earnings Revenues of $108.4 million compared to $100.6 million in the prior year periodPretax income of $7.0 million compared to $6.9 million in the prior year periodNew contract purchases of $391.1 million in the quarter LAS VEGAS, NV, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Consumer Portfolio Services, Inc. (Nasdaq: CPSS) (“CPS” or the “Company”) today announced earnings of $4.9 million, or $0.20 per diluted share, for its third quarter ended September 30, 2025. This represents an increase compared to net income of $4.8 million, or $0.20 per diluted share, in...
Tenaya Therapeutics Reports Third Quarter 2025 Financial Results and P...
Tenaya Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update Presentation of MyPEAK-1 Data and the American Heart Association Scientific Sessions Showed Consistent, Deeper, and Durable Improvement in Measures of Hypertrophy for Cohort 1 Patients Initial TN-201 Cohort 2 Data Demonstrated Early Dose Responsive Increases in TN-201 Transduction and MyBP-C Protein Expression Completed Dosing in Cohort 2 of RIDGE™-1 Trial of TN-401 for PKP2-associated ARVC; Cohort 1 Data On Track for Fourth Quarter Company Presentation Tenaya Management to Review New MyPEAK-1 ...
Tenaya Therapeutics Presents Promising Interim Clinical Data from MYPE...
Tenaya Therapeutics Presents Promising Interim Clinical Data from MYPEAK™-1 Phase 1b/2a Clinical Trial of TN-201 Gene Therapy for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy MyPEAK-1 Data Presented During Late-Breaking Session at AHA Scientific Sessions 2025 with Simultaneous Publication in Cardiovascular Research TN-201 Has Been Generally Well Tolerated at Both Doses Longer-term Follow Up of Cohort 1 Patients Showed Consistent, Deeper, and Durable Improvement in Measures of Hypertrophy Initial Cohort 2 Data Demonstrated Early Dose Responsive Increases in TN-201 Trans...
CPS to Host Conference Call on Third Quarter 2025 Earnings
CPS to Host Conference Call on Third Quarter 2025 Earnings LAS VEGAS, Nevada, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Consumer Portfolio Services, Inc. (Nasdaq: CPSS) (“CPS” or the “Company”) today announced that it will hold a conference call on Tuesday, November 11, 2025 at 1:00 p.m. ET to discuss its third quarter 2025 operating results. Those wishing to participate can pre-register for the conference call at the following link . Registered participants will receive an email containing conference call details for dial-in options. To avoid delays, we encourage participants to dial into the c...
MacroGenics to Participate in the Stifel 2025 Healthcare Conference
MacroGenics to Participate in the Stifel 2025 Healthcare Conference ROCKVILLE, MD, Nov. 06, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that Eric Risser, President and CEO of MacroGenics, will participate in a fireside chat at the Stifel 2025 Healthcare Conference on Thursday, November 13, 2025, at 4:00 pm ET in New York, NY. A webcast of the presentation may be accessed under "Events & Presentations" in the Investor Relations section of Mac...
Tenaya Therapeutics Announces New Clinical Data for TN-201 Gene Therap...
Tenaya Therapeutics Announces New Clinical Data for TN-201 Gene Therapy will be Featured in Late-Breaking Presentation at the American Heart Association Scientific Sessions 2025 Oral Presentation on Saturday to Highlight Interim Safety and Efficacy Results from the MyPEAK™-1 Phase 1b/2a Clinical Trial in Adults with MYBPC3-Associated Hypertrophic Cardiomyopathy Second Late-Breaking Presentation on Sunday to Showcase Results of Cellular Reprogramming Gene Therapy Treatment in Pig Model of Ischemic Heart Failure Tenaya Management to Host Webcast Conference Call on Monday, November 10, 2025,...
- Pierre FerraguÊ
NOW SERVICENOW INC.
DAI DAIMLER AG
WDC WESTERN DIGITAL CORPORATION
TER TERADYNE INC.
STX SEAGATE TECHNOLOGY PLC
MPWR MONOLITHIC POWER SYSTEMS INC.
GOOGL ALPHABET INC. CLASS A
GLW CORNING INC
FB FACEBOOK INC. CLASS A
EQIX EQUINIX INC.
CTSH COGNIZANT TECHNOLOGY SOLUTIONS CORPORATION CLASS A
AVT AVNET INC.
ARW ARROW ELECTRONICS INC.
ASM ASM INTERNATIONAL N.V.
AIXA AIXTRON SE
ASM PACIFIC TECHNOLOGY LIMITED
6723 RENESAS ELECTRONICS CORPORATION
8035 TOKYO ELECTRON LTD.
MELE MELEXIS NV
KLAC KLA CORPORATION
UMCB UNITED MICROELECTRONICS CORP (ADR)
AMZN AMAZON.COM INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
VOW VOLKSWAGEN (VOW GR)
CKP CHECKPOINT SYSTEMS INC
NET CLOUDFLARE INC CLASS A
CADE CADENCE BANK
TEAM ATLASSIAN CORPORATION
CLS CELESTICA INC.
5930 SAMSUNG GROUP
Kalaris Expands Leadership Team Appointing Matthew Gall, MBA, as Chief...
Kalaris Expands Leadership Team Appointing Matthew Gall, MBA, as Chief Financial Officer Highly experienced biopharma financial officer joins leadership team CFO hire bolsters Kalaris’ leadership team and supports continued growth of the company as it enrolls its Phase 1b/2 study in treatment naïve nAMD patients PALO ALTO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced the appointment of Matthew Gall, MB...
Kalaris to Present at Stifel 2025 Annual Healthcare Conference
Kalaris to Present at Stifel 2025 Annual Healthcare Conference PALO ALTO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced that management will present at the upcoming Stifel 2025 Annual Healthcare Conference. Details: Type: Company presentationSpeakers: Andrew Oxtoby, Chief Executive Officer & Matthew Feinsod, Chief Medical OfficerDate: Thursday, November 13, 2025Time: 3:20 – 3:50pm ET...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.